At Medicus, in collaboration with major local and Intermational Universities, we also perform qualified development of new chemical entities (NCEs), from extensive controlled laboratory testing, to sub contractual investigation in humans in accordance with applicable guidelines. early-stage product opportunities are support by university-based sponsored research.

Medicus is committed in ivestigating autoimmune disosters, cancer and infectious diseases by understanding the immune system. A new drug is under development. In addition to that, more than four partnered programs in cancer, infectious diseases and one synthetic therapeutic vaccine for the treatment of cancer are ongoing. The company is also developing preclinical compounds including a potent and specific angiogenesis inhibitor for testing cancer patients.